People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable ...

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

Phase 2 stage CT-388, a dual GLP-1/GIP receptor agonist injected ... It's difficult to judge if Roche can meet all the peak revenue targets it has set (see chart above), but the likelihood is ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what the ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist ... Roche/Genentech and sanofi-aventis. All grant and research support is managed by the University of California San Diego (CA, USA) and ...

Background and Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM). We aimed to evaluate the association ...

In short, failing to make the GLP-1 drugs widely affordable and available to all Americans is the proverbial case of being penny-wise and pound-foolish (and yes, the pun is intended.) We’re over the ...